Short- and long-term outcomes after laparoscopic versus open total gastrectomy for stage 0-I gastric cancer: a multicenter, retrospective analysis [0.03%]
腹腔镜全胃切除术与开腹全胃切除术治疗0至1期胃癌的短期和长期结局：一项多中心回顾性分析
Fangyao Zhou,Zaisheng Ye,Chengbin Zheng et al.
Fangyao Zhou et al.
Background: Laparoscopic surgery has been increasingly adopted in the treatment of gastric cancer. Although the safety and efficacy of laparoscopic distal gastrectomy have been well established, evidence regarding laparos...
Comparative Study
Chinese clinical oncology. 2026 Apr;15(2):29. DOI:10.21037/cco-2025-aw-152 2026
Fos-related antigen 1 is required for Helicobacter pylori-induced inflammatory response in gastric epithelial cells through NF-κB pathway [0.03%]
FOXA1通过NF-κB途径介导幽门螺杆菌对胃上皮细胞的炎症反应
Yang Yang,Shihe Shao
Yang Yang
Background: Chronic gastritis affects ~50% of the population, frequently linked to Helicobacter pylori (H. pylori). Fos-related antigen 1 (FRA-1) has been reported to be involved in stomach inflammation and malignancy. Th...
Is rechallenge with CDK4/6 inhibitors beyond progression reasonable for patients with hormone receptor-positive and HER2-negative advanced breast cancer?-a commentary on the PALMIRA trial [0.03%]
晚期激素受体阳性人类表皮生长因子受体2阴性乳腺癌患者病情进展后再次使用细胞周期蛋白依赖性激酶4/6抑制剂治疗合理吗？——PALMIRA试验述评
Mai Shimura,Toru Mukohara
Mai Shimura
Eribulin and trastuzumab in early-line HER2-positive metastatic breast cancer: evaluating an active chemotherapy partner in an evolving treatment landscape [0.03%]
早期HER2阳性转移性乳腺癌的厄洛替尼和曲妥珠单抗：在不断变化的治疗环境中评估一种有效的化疗伴侣药物
Hannah L Chang,Irene M Kang,Hope S Rugo
Hannah L Chang
Targeting metabolism in acute myeloid leukemia: the next therapeutic frontier? [0.03%]
靶向代谢是急性髓系白血病的下一个治疗前沿吗？
Alain Mina,Amer M Zeidan
Alain Mina
First-line fulvestrant vs. anastrozole in hormone receptor-positive advanced breast cancer: insights from the final FALCON trial results [0.03%]
FALCON试验最终结果解读：氟维司群一线治疗激素受体阳性晚期乳腺癌的疗效非劣效于阿那曲唑
Yuko Takahashi,Shogo Nakamoto,Maki Tanioka et al.
Yuko Takahashi et al.
Advancing precision oncology through innovative and adaptive master protocol designs: statistical, operational, and regulatory perspectives [0.03%]
创新自适应母方案设计促进精准肿瘤学的发展：统计、运营和监管角度
Jun Yin,Susan Geyer,Qian Shi et al.
Jun Yin et al.
Master protocol trials-including basket, umbrella, and platform designs-have revolutionized precision oncology by enabling the simultaneous evaluation of multiple therapies, biomarkers, and tumor subtypes within a unified adaptive framework...
Role of androgen receptor signaling in chemoresistance in urothelial cancer: a narrative review [0.03%]
雄激素受体信号在尿路上皮癌化学耐药中的作用：综述
Taro Akai,Gaku Yamamichi,Hiroshi Miyamoto
Taro Akai
Background and objective: Intravesical instillation of chemotherapeutic drugs remains a cornerstone in the management of non-muscle-invasive bladder tumor following transurethral surgery, where they are routinely employed...